JP2017160222A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160222A5
JP2017160222A5 JP2017079525A JP2017079525A JP2017160222A5 JP 2017160222 A5 JP2017160222 A5 JP 2017160222A5 JP 2017079525 A JP2017079525 A JP 2017079525A JP 2017079525 A JP2017079525 A JP 2017079525A JP 2017160222 A5 JP2017160222 A5 JP 2017160222A5
Authority
JP
Japan
Prior art keywords
fusion protein
integrin
pharmaceutical composition
binds
native sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017079525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017160222A (ja
JP6535361B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160222A publication Critical patent/JP2017160222A/ja
Publication of JP2017160222A5 publication Critical patent/JP2017160222A5/ja
Application granted granted Critical
Publication of JP6535361B2 publication Critical patent/JP6535361B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017079525A 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用 Expired - Fee Related JP6535361B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41135010P 2010-11-08 2010-11-08
US61/411,350 2010-11-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013537908A Division JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2017160222A JP2017160222A (ja) 2017-09-14
JP2017160222A5 true JP2017160222A5 (enExample) 2017-11-09
JP6535361B2 JP6535361B2 (ja) 2019-06-26

Family

ID=46051256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537908A Expired - Fee Related JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP2017079525A Expired - Fee Related JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013537908A Expired - Fee Related JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用

Country Status (7)

Country Link
US (3) US10844106B2 (enExample)
EP (2) EP3604549A1 (enExample)
JP (2) JP6170435B2 (enExample)
AU (3) AU2011326164B2 (enExample)
CA (1) CA2817197C (enExample)
DK (1) DK2638173T3 (enExample)
WO (1) WO2012064658A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
WO2012064658A1 (en) 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
JP2016505826A (ja) * 2012-12-10 2016-02-25 フレッド ハッチンソン キャンサー リサーチ センター スクリーニングの方法
PT2931265T (pt) 2012-12-14 2018-04-16 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US11013814B2 (en) 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CA2957717C (en) * 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
EP3313427A4 (en) * 2015-06-26 2018-12-26 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
JP6966424B2 (ja) 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
JP7308505B2 (ja) * 2016-01-08 2023-07-14 マキシオン セラピューティクス リミテッド 多様性を変化させた足場ドメインを有する結合メンバー
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2018044234A1 (en) * 2016-08-31 2018-03-08 Nanyang Technological University Cysteine-rich polypeptides and conjugates and methods of using the same
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
JP7191025B2 (ja) 2017-01-18 2022-12-16 フレッド ハッチンソン キャンサー センター Tead相互作用を妨害するためのペプチド組成物およびその使用方法
AU2018283161A1 (en) 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
CA3070230A1 (en) * 2017-07-24 2019-01-31 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CN113661240B (zh) * 2019-04-02 2024-11-05 伊莱利利公司 选择和检测结合肽的方法
EP3962511A4 (en) * 2019-04-29 2023-01-18 The Board of Trustees of the Leland Stanford Junior University METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT
US20220211861A1 (en) * 2019-05-22 2022-07-07 The Board of Trustees of the Leland Staford Junior University Drug conjugates and methods of using same
AU2020357806A1 (en) * 2019-09-30 2022-05-26 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
WO2022026906A2 (en) * 2020-07-30 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal targeting molecules comprising knottin peptides and related compositions and methods
MX2020012914A (es) * 2020-11-27 2022-05-30 Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6303749B1 (en) * 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP1358211A2 (en) 2001-01-31 2003-11-05 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP5912211B2 (ja) * 2004-01-20 2016-04-27 メルス ビー.ヴィー. 結合タンパク質の混合物
WO2006023420A2 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US7674881B2 (en) 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
WO2009018386A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009097017A2 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
US8394924B2 (en) 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
US8329826B2 (en) 2008-11-06 2012-12-11 The Board Of Trustees Of The Leland Stanford Junior University Surface modification of interpenetrating polymer networks
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CA2786149C (en) 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2012064658A1 (en) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein

Similar Documents

Publication Publication Date Title
JP2017160222A5 (enExample)
JP2019522490A5 (enExample)
CN111148756B (zh) T细胞受体
US20220119493A1 (en) Il-7r-alpha binding compounds
JP2016053091A5 (enExample)
JP2018198596A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2023081303A5 (enExample)
JP2014519830A5 (enExample)
JP2013505734A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2013537416A5 (enExample)
JP2018511327A5 (enExample)
JP2012501959A5 (enExample)
JP2014523238A5 (enExample)
JP2015505299A5 (enExample)
JP2017113019A5 (enExample)
JP2010202664A5 (enExample)
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
JP2018512124A5 (enExample)
JP2013529178A5 (enExample)
JP2016508143A5 (enExample)
JP2009520758A5 (enExample)
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
JP2005502663A5 (enExample)